Barrett's oesophagus, oesophageal cancer and colon cancer: An explanation of the association and cancer chemopreventive potential of non- steroidal anti-inflammatory drugs

European Journal of Cancer Prevention

Volumn 7, Issue 3, 1998, Pages 195-199

  Morgan, G ^a   Vainio, H ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cancer prevention; Cyclooxygenase inhibitors; Predisposition

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P53; SULINDAC;

ALCOHOL CONSUMPTION; ARTICLE; BARRETT ESOPHAGUS; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; COLON ADENOMA; COLON CARCINOMA; COLON POLYPOSIS; COLORECTAL CANCER; DIET; ESOPHAGUS CARCINOMA; HUMAN; PRIORITY JOURNAL; SMOKING; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARRETT ESOPHAGUS; CAUSALITY; CHEMOPREVENTION; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; ESOPHAGEAL NEOPLASMS; HUMANS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS;

EID: 0031817778     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-199806000-00003     Document Type: Article

References (25)

1. Achkar JP, Post AB, Achkar E, Carey WD (1995). Risk of extraesophageal malignancy in patients with adenocarcinoma arising in Barrett's esophagus. Am J Gastroenterol 90(1): 39-43.
2. Barrett NR (1957). The lower esophagus lined by columnar epithelium. Surgery 41: 881-94.
3. Cameron AJ, Lomboy CT (1992). Barrett's esophagus: age, prevalence and extent of columnar epithelium. Gastroenterol 103: 1241-5.
4. Cauvin J-M, Goldfain D, Rhun ML et al (1995). Multicentre prospective study of Barrett's oesophagus and colorectal adenomas. Lancet 346: 1391-4.
5. Ekstrom P, Carling L, Wetterhus S et al (1996). Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol 31: 753-8.
6. Fein M (1997). APC gene alterations in Barrett's metaplasia are implicated at an early stage in the carcinogenesis of esophageal adenocarcinoma. Am J Gastroenterol 97(2): 359-60.
7. Fu S, Ramanujam KS, Meitzer SJ, Wilson KT (1997). Expression and localization of inducible nitric oxide synthase and cyclooxygense-2 in Barrett's esophagus. Gastroenterol 114(2): A565.
8. Funkhouser EM, Sharp GA (1995). Aspirin and the reduced risk of esophageal carcinoma. Cancer 76(7): 1116-9.
9. Howden CW, Hornung CA (1995). A systematic review of the association between Barrett's esophagus and colon neoplasms. Am J Gastroenterol 90(10): 1814-9.
10. IARC Handbooks of Cancer Prevention (1998). Volume 1: Non-Steroidal Anti-Inflammatory Drugs. International Agency for Research on Cancer, Lyon.
11. Kumble S, Omary MB, Cartwright CA, Triadafilopoulos G (1997). Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterol 112(2): 348-56.
12. Kune GA, Vitteta L (1995). The causes of ordinary colorectal adenomas: the key to control of colorectal cancers? J R Soc Med 88: 625-8.
13. Montesano R, Hollstein M, Hainuit P (1996). Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 69: 225-35.
14. Morgan GP (1996). Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers. Gut 38: 646-8.
15. Morgan GP, Williams JG (1994). Inflammatory mediators in the oesophagus. Gut 35: 297-8.
16. Oka M, Attwood SE, Kaw B, Smyrk TC, DeMeester TR (1992). Immunosuppression in patients with Barrett's esophagus. Surgery 112(1): 11-7.
17. Prescott SM, White RL (1996). Self promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 87: 783-6.
18. Richter JE, Falk GW (1996). Barrett's esophagus and adenocarcinoma: the need for a consensus conference. J Clin Gastroenterol 23(2): 88-90.
19. Ritenbaugh C, Sampliner R, Aickin M, Garewal H, Meyskens F (1995). Risk factors for Barrett's oesophagus: a life history approach to behavioural assessment in the distant past. Eur J Cancer Prev 4(6): 459-68.
20. Schnitzler M, Dwight T, Robinson TG (1996). Sulindac increases the expression of APC mRNA in malignant colonic epithelial cell lines: an in vitro study. Gut 38: 707-13.
21. Sontag SJ, Schnell TG, Chejfec G (1985). Barrett's esophagus and colonic tumours. Lancet 1: 946-9.
22. Stein HJ, Siewert JR (1993). Barrett's esophagus: pathogenesis, epidemiology, functional abnormalities, malignant degeneration and surgical management. Dysphagia 8(3): 276-88.
23. Subbaramaiah K, Telng N, Ramonetti JT et al (1996). Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56(19): 4424-9.
24. Van der Burgh A, Dees J, Hop WJC, van Blankenstein M (1996). Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 39: 5-8.
25. Zhuang Z, Vortmeyer AO, Mark EJ (1996). Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive carcinomas. Cancer Res 56: 1961-4.